secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tonix Pharmaceuticals Holding Corp. (TNXP)
CIK:        0001430306
Form:       8-K
Filed at:   2025-12-09T23:59:59+00:00
Accession:  0001999371-25-019833
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tonix Pharmaceuticals appoints Irina Ishak as General Counsel effective Dec 8, 2025
--------------------------------------------------------------------------------

- Irina Ishak joins from Lowenstein Sandler LLP where she was Senior Counsel since 2013.
- She previously advised Tonix since 2017 on financings, licensing, and corporate governance.
- Ms. Ishak brings over 25 years of legal experience in life sciences, including at Savient Pharmaceuticals.
- Tonix recently launched TONMYA for fibromyalgia, first new FDA-approved treatment in over 15 years.
- Seth Lederman, CEO, highlights her expertise in complex transactions and public company matters.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1430306/000199937125019833/0001999371-25-019833-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1430306/000199937125019833/tonix-8k_120925.htm
  HTML page:      https://secwatch.observer/filing/0001999371-25-019833

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer